Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Breast Cancer

  Free Subscription


12.03.2018

3 Am J Surg
5 Ann Surg Oncol
7 Anticancer Res
3 BMC Cancer
2 Breast Cancer
1 Breast Cancer (Auckl)
4 Breast Cancer Res
9 Breast Cancer Res Treat
12 Breast J
2 Cancer
1 Cancer Lett
1 Cancer Res
1 Clin Breast Cancer
2 Clin Cancer Res
1 Eur Radiol
2 Exp Cell Res
1 Gene
1 Histopathology
2 Int J Cancer
2 Int J Oncol
1 J Biol Chem
1 J Clin Oncol
5 Lancet Oncol
1 N Engl J Med
1 Nat Rev Clin Oncol
1 Oncol Rep
2 Oncology
1 Oncology (Williston Park)
5 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Am J Surg

  1. DEBARROS M
    The significance and impact of pathogenic and variants of unknown significance (VUS) mutations in breast cancer patients and their treatment decisions.
    Am J Surg. 2018 Feb 15. pii: S0002-9610(17)31692.
    PubMed     Text format    

  2. WARREN SL, Bhutiani N, Agle SC, Martin RCG 2nd, et al
    Differences between palpable and nonpalpable tumors in early-stage, hormone receptor-positive breast cancer.
    Am J Surg. 2018 Feb 17. pii: S0002-9610(17)31373.
    PubMed     Text format     Abstract available


  3. Discussion of: Neoadjuvant systemic therapy in invasive lobular breast cancer: Is it indicated?
    Am J Surg. 2018;215:513-514.
    PubMed     Text format    


    Ann Surg Oncol

  4. TURASHVILI G, Gonzalez-Loperena M, Brogi E, Dickler M, et al
    The 21-Gene Recurrence Score in Male Breast Cancer.
    Ann Surg Oncol. 2018 Mar 8. pii: 10.1245/s10434-018-6411.
    PubMed     Text format     Abstract available

  5. OCHOA O, Azouz V, Santillan A, Pisano S, et al
    Internal Mammary Lymph Node Biopsy During Free-Flap Breast Reconstruction: Optimizing Adjuvant Breast Cancer Treatment Through Comprehensive Staging.
    Ann Surg Oncol. 2018 Mar 1. pii: 10.1245/s10434-018-6352.
    PubMed     Text format     Abstract available

  6. VAN DER NOORDAA MEM, van Duijnhoven FH, Straver ME, Groen EJ, et al
    Major Reduction in Axillary Lymph Node Dissections After Neoadjuvant Systemic Therapy for Node-Positive Breast Cancer by combining PET/CT and the MARI Procedure.
    Ann Surg Oncol. 2018 Mar 6. pii: 10.1245/s10434-018-6404.
    PubMed     Text format     Abstract available

  7. DE LA CRUZ LM, Shulman LN
    'Under' Surveillance: Impact of Race and Socioeconomic Status on Post-Treatment Breast Cancer Imaging.
    Ann Surg Oncol. 2018 Mar 7. pii: 10.1245/s10434-018-6418.
    PubMed     Text format    

  8. PATEL BK, Hilal T, Covington M, Zhang N, et al
    Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic Therapy.
    Ann Surg Oncol. 2018 Mar 7. pii: 10.1245/s10434-018-6413.
    PubMed     Text format     Abstract available


    Anticancer Res

  9. DE CREMOUX P, Hamy AS, Lehmann-Che J, Scott V, et al
    COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients.
    Anticancer Res. 2018;38:1485-1490.
    PubMed     Text format     Abstract available

  10. HA GH, Kim DY, Breuer EK, Kim CK, et al
    Combination Treatment of Polo-Like Kinase 1 and Tankyrase-1 Inhibitors Enhances Anticancer Effect in Triple-negative Breast Cancer Cells.
    Anticancer Res. 2018;38:1303-1310.
    PubMed     Text format     Abstract available

  11. DIMAS DT, Perlepe CD, Sergentanis TN, Misitzis I, et al
    The Prognostic Significance of Hsp70/Hsp90 Expression in Breast Cancer: A Systematic Review and Meta-analysis.
    Anticancer Res. 2018;38:1551-1562.
    PubMed     Text format     Abstract available

  12. KOI Y, Koga C, Akiyoshi S, Masuda T, et al
    Impact of Visceral Metastasis on Efficacy of Fulvestrant in Patients with Hormone Receptor-positive Recurrent Breast Cancer.
    Anticancer Res. 2018;38:1579-1584.
    PubMed     Text format     Abstract available

  13. FRITZ P, Dippon J, Muller S, Goletz S, et al
    Is Mistletoe Treatment Beneficial in Invasive Breast Cancer? A New Approach to an Unresolved Problem.
    Anticancer Res. 2018;38:1585-1593.
    PubMed     Text format     Abstract available

  14. ALEXOPOULOU E, Katsila T, Tolia M, Tsoukalas N, et al
    An Exploratory Study of Radiation Dermatitis in Breast Cancer Patients.
    Anticancer Res. 2018;38:1615-1622.
    PubMed     Text format     Abstract available

  15. GOMES I, Miranda A, Nunes C
    Spatiotemporal Analysis of Breast Cancer Incidence: A Study in Southern Portugal Between 2005 and 2012.
    Anticancer Res. 2018;38:1797-1805.
    PubMed     Text format     Abstract available


    BMC Cancer

  16. VONDELING GT, Menezes GL, Dvortsin EP, Jansman FGA, et al
    Burden of early, advanced and metastatic breast cancer in The Netherlands.
    BMC Cancer. 2018;18:262.
    PubMed     Text format     Abstract available

  17. YANG L, Wang J, Cheng J, Wang Y, et al
    Quality assurance target for community-based breast cancer screening in China: a model simulation.
    BMC Cancer. 2018;18:261.
    PubMed     Text format     Abstract available

  18. ENGEL C, Rhiem K, Hahnen E, Loibl S, et al
    Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
    BMC Cancer. 2018;18:265.
    PubMed     Text format     Abstract available


    Breast Cancer

  19. YOSHIMURA A, Okumura S, Sawaki M, Hattori M, et al
    Feasibility study of contralateral risk-reducing mastectomy with breast reconstruction for breast cancer patients with BRCA mutations in Japan.
    Breast Cancer. 2018 Mar 8. pii: 10.1007/s12282-018-0850.
    PubMed     Text format     Abstract available

  20. KA WH, Cho SK, Chun BN, Byun SY, et al
    The ubiquitin ligase COP1 regulates cell cycle and apoptosis by affecting p53 function in human breast cancer cell lines.
    Breast Cancer. 2018 Mar 7. pii: 10.1007/s12282-018-0849.
    PubMed     Text format     Abstract available


    Breast Cancer (Auckl)

  21. SYRIOS J, Pappa E, Volakakis N, Grivas A, et al
    Real-World Data on Health-Related Quality of Life Assessment in Patients With Breast Cancer Receiving Subcutaneous Trastuzumab.
    Breast Cancer (Auckl). 2018;12:1178223418758031.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  22. BRAMAN NM, Etesami M, Prasanna P, Dubchuk C, et al
    Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.
    Breast Cancer Res. 2017;19:57.
    PubMed     Text format     Abstract available

  23. KIM H, Lin Q, Glazer PM, Yun Z, et al
    The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells.
    Breast Cancer Res. 2018;20:16.
    PubMed     Text format     Abstract available

  24. SAMENI M, Cavallo-Medved D, Franco OE, Chalasani A, et al
    Pathomimetic avatars reveal divergent roles of microenvironment in invasive transition of ductal carcinoma in situ.
    Breast Cancer Res. 2017;19:56.
    PubMed     Text format     Abstract available

  25. BOYD N, Berman H, Zhu J, Martin LJ, et al
    The origins of breast cancer associated with mammographic density: a testable biological hypothesis.
    Breast Cancer Res. 2018;20:17.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  26. BAO T, Iris Zhi W, Vertosick EA, Li QS, et al
    Acupuncture for breast cancer-related lymphedema: a randomized controlled trial.
    Breast Cancer Res Treat. 2018 Mar 8. pii: 10.1007/s10549-018-4743.
    PubMed     Text format     Abstract available

  27. BLANCHETTE PS, Desautels DN, Pond GR, Bartlett JMS, et al
    Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab.
    Breast Cancer Res Treat. 2018 Mar 8. pii: 10.1007/s10549-018-4734.
    PubMed     Text format     Abstract available

  28. PARK SJ, Lee MH, Kong SY, Song MK, et al
    Use of adjuvant chemotherapy in hormone receptor-positive breast cancer patients with or without the 21-gene expression assay.
    Breast Cancer Res Treat. 2018 Mar 8. pii: 10.1007/s10549-018-4740.
    PubMed     Text format     Abstract available

  29. ADAMS BD, Arem H, Hubal MJ, Cartmel B, et al
    Exercise and weight loss interventions and miRNA expression in women with breast cancer.
    Breast Cancer Res Treat. 2018 Mar 6. pii: 10.1007/s10549-018-4738.
    PubMed     Text format     Abstract available

  30. VELASQUEZ GARCIA HA, Sobolev BG, Gotay CC, Wilson CM, et al
    Mammographic non-dense area and breast cancer risk in postmenopausal women: a causal inference approach in a case-control study.
    Breast Cancer Res Treat. 2018 Mar 7. pii: 10.1007/s10549-018-4737.
    PubMed     Text format     Abstract available

  31. ONEGA T, Zhu W, Weiss JE, Goodrich M, et al
    Preoperative breast MRI and mortality in older women with breast cancer.
    Breast Cancer Res Treat. 2018 Mar 7. pii: 10.1007/s10549-018-4732.
    PubMed     Text format     Abstract available

  32. RICE MS, Tamimi RM, Bertrand KA, Scott CG, et al
    Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics.
    Breast Cancer Res Treat. 2018 Mar 3. pii: 10.1007/s10549-018-4735.
    PubMed     Text format     Abstract available

  33. GERNAAT SAM, Boer JMA, van den Bongard DHJ, Maas AHEM, et al
    The risk of cardiovascular disease following breast cancer by Framingham risk score.
    Breast Cancer Res Treat. 2018 Feb 28. pii: 10.1007/s10549-018-4723.
    PubMed     Text format     Abstract available

  34. CHOWDHURY M, Euhus D, O'Donnell M, Onega T, et al
    Dose-dependent effect of mammographic breast density on the risk of contralateral breast cancer.
    Breast Cancer Res Treat. 2018 Mar 6. pii: 10.1007/s10549-018-4736.
    PubMed     Text format     Abstract available


    Breast J

  35. O'SHEA E, O'Reilly S, Smiddy P
    Rare imaging appearance of skeletal metastases in a 61-year-old breast cancer patient.
    Breast J. 2018 Mar 2. doi: 10.1111/tbj.13019.
    PubMed     Text format    

  36. YADAV S, Jinna S, Pereira-Rodrigues O, Reeves A, et al
    Impact of preoperative BRCA1/2 testing on surgical decision making in patients with newly diagnosed breast cancer.
    Breast J. 2018 Mar 2. doi: 10.1111/tbj.13007.
    PubMed     Text format     Abstract available

  37. SMITH IORFIDO SM, Makariou E
    Empyema necessitans mimicking inflammatory breast cancer-An unusual case of breast edema.
    Breast J. 2018 Mar 2. doi: 10.1111/tbj.13015.
    PubMed     Text format    

  38. TOZBIKIAN GH, Zynger DL
    HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX.
    Breast J. 2018 Mar 2. doi: 10.1111/tbj.13004.
    PubMed     Text format     Abstract available

  39. VOHRA NA, Brinkley J, Kachare S, Muzaffar M, et al
    Primary tumor resection in metastatic breast cancer: A propensity-matched analysis, 1988-2011 SEER data base.
    Breast J. 2018 Mar 2. doi: 10.1111/tbj.13005.
    PubMed     Text format     Abstract available

  40. KAMAL M, Nafie EHO, Elsers S, Alanwar S, et al
    Ethnicity influences breast cancer stem cells' drug resistance.
    Breast J. 2018 Mar 2. doi: 10.1111/tbj.13021.
    PubMed     Text format    

  41. HANLEY BP, Walsh SM, O'Leary DP, MacNally SP, et al
    The significance of receptor status discordance between breast cancer primary and brain metastasis.
    Breast J. 2018 Mar 8. doi: 10.1111/tbj.13028.
    PubMed     Text format    

  42. DIALANI V, Westra C, Venkataraman S, Fein-Zachary V, et al
    Indications for biopsy of imaging-detected intramammary and axillary lymph nodes in the absence of concurrent breast cancer.
    Breast J. 2018 Mar 8. doi: 10.1111/tbj.13009.
    PubMed     Text format     Abstract available

  43. CLIFTON K, Barnett C, Martinez A, Karuturi M, et al
    Severe hyponatremia following cyclophosphamide infusion in breast cancer patients.
    Breast J. 2018 Mar 2. doi: 10.1111/tbj.13026.
    PubMed     Text format    

  44. BARCO I, Fraile M, Vidal M, Cambra MJ, et al
    Tamoxifen induced radiation recall dermatitis in a breast cancer patient.
    Breast J. 2018 Mar 8. doi: 10.1111/tbj.13014.
    PubMed     Text format    

  45. VIEIRA RADC, Silveira SFDS, Silva DRD, Tramonte MS, et al
    Knowledge and attitudes about breast cancer care in female inmates in Sao Paulo State/Brazil.
    Breast J. 2018 Mar 8. doi: 10.1111/tbj.13025.
    PubMed     Text format    

  46. UNKART JT, Proudfoot J, Wallace AM
    Outcomes of "one-day" vs "two-day" injection protocols using Tc-99m tilmanocept for sentinel lymph node biopsy in breast cancer.
    Breast J. 2018 Mar 2. doi: 10.1111/tbj.13002.
    PubMed     Text format     Abstract available


    Cancer

  47. SCHWARTZ KL, Simon MS, Bylsma LC, Ruterbusch JJ, et al
    Clinical and economic burden associated with stage III to IV triple-negative breast cancer: A SEER-Medicare historical cohort study in elderly women in the United States.
    Cancer. 2018 Mar 5. doi: 10.1002/cncr.31299.
    PubMed     Text format     Abstract available

  48. FREEDMAN RA, Keating NL, Lin NU, Winer EP, et al
    Breast cancer-specific survival by age: Worse outcomes for the oldest patients.
    Cancer. 2018 Mar 2. doi: 10.1002/cncr.31308.
    PubMed     Text format     Abstract available


    Cancer Lett

  49. HU Y, Yague E, Zhao J, Wang L, et al
    Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer.
    Cancer Lett. 2018 Feb 26. pii: S0304-3835(18)30177.
    PubMed     Text format     Abstract available


    Cancer Res

  50. LUAN H, Mohapatra B, Bielecki TA, Mushtaq I, et al
    Loss of the nuclear pool of ubiquitin ligase CHIP/STUB1 in breast cancer unleashes the MZF1-cathepsin pro-oncogenic program.
    Cancer Res. 2018 Mar 6. pii: 0008-5472.CAN-16-2140.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  51. WU JD, Hong CQ, Huang WH, Wei XL, et al
    L1 Cell Adhesion Molecule and Its Soluble Form sL1 Exhibit Poor Prognosis in Primary Breast Cancer Patients.
    Clin Breast Cancer. 2017 Dec 28. pii: S1526-8209(17)30523.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  52. RICCIARDELLI C, Bianco-Miotto T, Jindal S, Butler LM, et al
    The Magnitude of Androgen Receptor Positivity in Breast Cancer is Critical for Reliable Prediction of Disease Outcome.
    Clin Cancer Res. 2018 Mar 7. pii: 1078-0432.CCR-17-1199.
    PubMed     Text format     Abstract available

  53. LIU L, Yang L, Yan W, Zhai J, et al
    Chemotherapy induces breast cancer stemness in association with dysregulated monocytosis.
    Clin Cancer Res. 2018 Mar 2. pii: 1078-0432.CCR-17-2545.
    PubMed     Text format     Abstract available


    Eur Radiol

  54. KIM SY, Shin J, Kim DH, Kim EK, et al
    Correlation between electrical conductivity and apparent diffusion coefficient in breast cancer: effect of necrosis on magnetic resonance imaging.
    Eur Radiol. 2018 Mar 6. pii: 10.1007/s00330-017-5291.
    PubMed     Text format     Abstract available


    Exp Cell Res

  55. LI K, Yan H, Guo W, Tang M, et al
    ATM inhibition induces synthetic lethality and enhances sensitivity of PTEN-deficient breast cancer cells to cisplatin.
    Exp Cell Res. 2018 Mar 6. pii: S0014-4827(18)30125.
    PubMed     Text format     Abstract available

  56. YAMASHITA N, Saito N, Zhao S, Terai K, et al
    Heregulin-induced cell migration is promoted by aryl hydrocarbon receptor in HER2-overexpressing breast cancer cells.
    Exp Cell Res. 2018 Mar 1. pii: S0014-4827(18)30116.
    PubMed     Text format     Abstract available


    Gene

  57. XIAO B, Zhang W, Chen L, Hang J, et al
    Analysis of the miRNA-mRNA-lncRNA network in human estrogen receptor-positive and estrogen receptor-negative breast cancer based on TCGA data.
    Gene. 2018 Mar 5. pii: S0378-1119(18)30238-5. doi: 10.1016/j.gene.2018.
    PubMed     Text format     Abstract available


    Histopathology

  58. BULTE JP, Halilovic A, Kalkman S, van Cleef PHJ, et al
    Assessment of HER2 status in breast cancer biopsies is not affected by accelerated tissue processing.
    Histopathology. 2018 Mar 1. doi: 10.1111/his.13507.
    PubMed     Text format     Abstract available


    Int J Cancer

  59. ABUBAKAR M, Chang-Claude J, Ali HR, Chatterjee N, et al
    Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation.
    Int J Cancer. 2018 Mar 1. doi: 10.1002/ijc.31352.
    PubMed     Text format     Abstract available

  60. WRIGHT LB, Schoemaker MJ, Jones ME, Ashworth A, et al
    Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study.
    Int J Cancer. 2018 Mar 8. doi: 10.1002/ijc.31364.
    PubMed     Text format     Abstract available


    Int J Oncol

  61. MIYAGAWA Y, Matsushita Y, Suzuki H, Komatsu M, et al
    Frequent downregulation of LRRC26 by epigenetic alterations is involved in the malignant progression of triple-negative breast cancer.
    Int J Oncol. 2018 Mar 5. doi: 10.3892/ijo.2018.4301.
    PubMed     Text format     Abstract available

  62. DI D, Chen L, Guo Y, Wang L, et al
    BCSC-1 suppresses human breast cancer metastasis by inhibiting NF-kappaB signaling.
    Int J Oncol. 2018 Mar 7. doi: 10.3892/ijo.2018.4309.
    PubMed     Text format     Abstract available


    J Biol Chem

  63. ITOU J, Li W, Ito S, Tanaka S, et al
    Sal-like 4 protein levels in breast cancer cells are post-translationally down-regulated by tripartite motif containing 21.
    J Biol Chem. 2018 Mar 6. pii: RA117.000245. doi: 10.1074/jbc.RA117.000245.
    PubMed     Text format     Abstract available


    J Clin Oncol

  64. WEDAM SB, Beaver JA, Amiri-Kordestani L, Bloomquist E, et al
    US Food and Drug Administration Pooled Analysis to Assess the Impact of Bone-Only Metastatic Breast Cancer on Clinical Trial Outcomes and Radiographic Assessments.
    J Clin Oncol. 2018 Mar 9:JCO2017746917. doi: 10.1200/JCO.2017.74.6917.
    PubMed     Text format     Abstract available


    Lancet Oncol

  65. CHARALAMPOUDIS P, Karakatsanis A
    Neoadjuvant chemotherapy for early breast cancer.
    Lancet Oncol. 2018;19:e128.
    PubMed     Text format    

  66. KRUG D, Loibl S
    Neoadjuvant chemotherapy for early breast cancer.
    Lancet Oncol. 2018;19:e129.
    PubMed     Text format    

  67. MCGALE P, Dodwell D, Taylor C, Gray R, et al
    Neoadjuvant chemotherapy for early breast cancer - Author's reply.
    Lancet Oncol. 2018;19:e130.
    PubMed     Text format    

  68. LOIBL S, O'Shaughnessy J, Untch M, Sikov WM, et al
    Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Lancet Oncol. 2018 Feb 28. pii: S1470-2045(18)30111.
    PubMed     Text format     Abstract available

  69. CURIGLIANO G
    Addition of platinum salts to neoadjuvant chemotherapy in triple-negative breast cancer: a new standard of care?
    Lancet Oncol. 2018 Feb 28. pii: S1470-2045(18)30129.
    PubMed     Text format    


    N Engl J Med

  70. ANDERSON GM
    Breast-Cancer Recurrence after Stopping Endocrine Therapy.
    N Engl J Med. 2018;378:870.
    PubMed     Text format    


    Nat Rev Clin Oncol

  71. SIDAWAY P
    Breast cancer: Fibroblast subtypes alter the microenvironment.
    Nat Rev Clin Oncol. 2018 Mar 6. pii: nrclinonc.2018.
    PubMed     Text format    


    Oncol Rep

  72. XU W, Wu B, Fu L, Chen J, et al
    Comparison of three different methods for the detection of circulating tumor cells in mice with lung metastasis.
    Oncol Rep. 2017;37:3219-3226.
    PubMed     Text format     Abstract available


    Oncology

  73. ISHITOBI M, Fukui R, Hashimoto Y, Kittaka N, et al
    pTis and pT1a Ipsilateral Breast Tumor Recurrence Is Associated with Good Prognosis after Salvage Surgery.
    Oncology. 2018;94:12-18.
    PubMed     Text format     Abstract available

  74. JIA S, Miedel MT, Ngo M, Hessenius R, et al
    Clinically Observed Estrogen Receptor Alpha Mutations within the Ligand-Binding Domain Confer Distinguishable Phenotypes.
    Oncology. 2018;94:176-189.
    PubMed     Text format     Abstract available


    Oncology (Williston Park)

  75. SHACHAR SS, Jolly TA, Jones E, Muss HB, et al
    Management of Triple-Negative Breast Cancer in Older Patients: How Is It Different?
    Oncology (Williston Park). 2018;32:58-63.
    PubMed     Text format     Abstract available


    PLoS One

  76. DE GROEF A, Van Kampen M, Moortgat P, Anthonissen M, et al
    An evaluation tool for Myofascial Adhesions in Patients after Breast Cancer (MAP-BC evaluation tool): Concurrent, face and content validity.
    PLoS One. 2018;13:e0193915.
    PubMed     Text format     Abstract available

  77. HUSSAIN A, Yong C, Tkaczuk KHR, Qian Y, et al
    Prevalence and risk of skeletal complications and use of radiation therapy in elderly women diagnosed with metastatic breast cancer.
    PLoS One. 2018;13:e0193661.
    PubMed     Text format     Abstract available

  78. ALMOTWAA S, Elrobh M, AbdulKarim H, Alanazi M, et al
    Genetic polymorphism and expression of HSF1 gene is significantly associated with breast cancer in Saudi females.
    PLoS One. 2018;13:e0193095.
    PubMed     Text format     Abstract available

  79. VREEMANN S, Gubern-Merida A, Borelli C, Bult P, et al
    The correlation of background parenchymal enhancement in the contralateral breast with patient and tumor characteristics of MRI-screen detected breast cancers.
    PLoS One. 2018;13:e0191399.
    PubMed     Text format     Abstract available

  80. BOSE C, Awasthi S, Sharma R, Benes H, et al
    Sulforaphane potentiates anticancer effects of doxorubicin and attenuates its cardiotoxicity in a breast cancer model.
    PLoS One. 2018;13:e0193918.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: